Vertex executives warned that Casgevy, its curative treatment for sickle cell disease, would be slow to reach patients. But ...
The trail enrolled 123 patients at 23 sites across the US and Europe.
Jupiter Endovascular announced that it completed patient enrollment in the SPIRARE II pivotal clinical trial evaluating its Vertex system.
Zacks Investment Research on MSN
Is trending stock Vertex Pharmaceuticals Incorporated (VRTX) a buy now?
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
China-based biologics CDMO WuXi Biologics (HKEX: 2269) has signed a license and research services agreement with US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) covering a preclinical trispecific ...
1d
Is Vertex Pharmaceuticals (VRTX) Pricing Reflect Long Term Cash Flow Potential After Recent Pullback
Wondering if Vertex Pharmaceuticals at around US$470 a share is offering fair value, or if you are paying up for quality, you ...
The biotech could be on the verge of expanding its lineup and entering a new era of growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results